We challenged a panel of 31 non-small cell lung cancer (NSCLC) cell lines with a novel, potent and selective inhibitor of thioredoxin reductase 1 (TXNRD1), recently developed by our group [6], for its central role in redox regulation. Here, TXNRD1 is linked to non-small cell lung carcinoma.